1. Introduction {#sec1-cancers-11-01798}
===============

Cancer immunotherapy using immune checkpoint inhibitors (ICIs) is approved for several malignancies \[[@B1-cancers-11-01798],[@B2-cancers-11-01798]\]. Although some patients experience significant clinical benefit from ICIs, others have no or limited clinical benefit \[[@B3-cancers-11-01798],[@B4-cancers-11-01798],[@B5-cancers-11-01798]\], in some cases also accompanied by severe side effects. Therefore, discovering biomarkers that can identify patients who may benefit from ICIs is crucial. The programmed death-ligand 1 (PD-L1) expression density is widely used and thus far the only biomarker in clinical routine in various cancer entities. It was approved by the US Food and Drug Administration as a companion diagnostic tool \[[@B6-cancers-11-01798],[@B7-cancers-11-01798]\]. A recent meta-analysis demonstrated that programmed cell death protein 1 (PD-1) or PD-L1 blockade therapy could decrease the risk of death by 28% in comparison to conventional treatment. Moreover, a greater risk reduction was achieved in patients positive for PD-L1 (34%) compared to those with negative staining (20%) \[[@B8-cancers-11-01798]\], providing robust evidence for the clinical efficacy of ICIs, especially in patients with PD-L1-positive tumors. However, PD-L1 expression as a predictive biomarker has many limitations. It may change over time or upon the initiation of treatments such as chemotherapy and radiotherapy \[[@B9-cancers-11-01798]\]. Tumor may be show heterogenous PD-L1 expression, and small biopsies or tumor microarrays may miss PD-L1 expression and give discrepant results from surgically resected tissue samples \[[@B9-cancers-11-01798]\]. Pre-analytical factors such as types of fixative and duration of fixation, differences in detecting techniques such as antibody reagents and immunohistochemistry platforms, differences in definitions of cut-offs and poor observer reproducibility account for different results of PD-L1 expression \[[@B9-cancers-11-01798],[@B10-cancers-11-01798],[@B11-cancers-11-01798]\]. Positive PD-L1 may also be induced by inflammatory procedures, such as release of interferon and T-cell recognition, which can be driven by PD-1 inhibition \[[@B12-cancers-11-01798]\]. In several phase III randomized controlled trials (RCTs), PD-L1 immunohistochemistry has not fulfilled its promise as a predictive biomarker \[[@B4-cancers-11-01798],[@B13-cancers-11-01798],[@B14-cancers-11-01798],[@B15-cancers-11-01798]\], showing significant risk reduction rates with ICIs even in patients with negative PD-L1 staining. Therefore, it is difficult to select patients for ICI therapy using PD-L1 expression alone \[[@B8-cancers-11-01798],[@B16-cancers-11-01798]\]. Identification of putative biomarkers that can better predict ICI efficacy and thereby allow better patient selection is of the utmost clinical need in terms of economic considerations and immune-related adverse effects \[[@B17-cancers-11-01798],[@B18-cancers-11-01798],[@B19-cancers-11-01798]\].

Recently, tumor-specific features derived from genome-wide analysis emerged as effective biomarkers to predict the response to ICI treatment \[[@B20-cancers-11-01798],[@B21-cancers-11-01798],[@B22-cancers-11-01798]\]. It was suggested that a higher frequency of gene mutations, denoted as tumor mutational burden (TMB), increase the likelihood of generating immunogenic tumor neoantigens recognized by the host immune system \[[@B20-cancers-11-01798],[@B21-cancers-11-01798],[@B22-cancers-11-01798]\]. As a direct indicator of immune recognition, neoantigen load was initially studied as a promising candidate \[[@B21-cancers-11-01798]\]. Although mutational load, neoantigen load and expression of cytolytic markers in the immune microenvironment were associated with clinical benefit after ipilimumab treatment, there was no recurrent neoantigen peptide sequence which predicted response \[[@B21-cancers-11-01798]\]. It was recently reported that TMB is more predictive concerning the clinical benefit from ICIs than neoantigen load using either a moderate or strong threshold to patient-specific class I human leukocyte antigen (HLA) alleles \[[@B23-cancers-11-01798]\]. Thus, TMB was investigated as an emerging biomarker for prediction of response to ICI treatments. In patients who received anti-PD-1 or anti-PD-L1 monotherapy involving 27 tumor types or subtypes, Yarchoan et al. \[[@B24-cancers-11-01798]\] showed that the response rate correlated with TMB. Although there has been a growing body of evidence revealing a better response in patients with higher TMB treated by ICIs, studies exploring the interaction between TMB and the long-term efficacy of ICI treatments are limited by the relatively inadequate power of primary studies, mainly due to their exploratory nature.

Current investigations are attempting to validate the long-term oncologic impact of TMB from two perspectives. One is the role of TMB as a predictive biomarker of ICI treatment and the other is the efficacy of ICI treatment compared to conventional treatment in groups of patients with different TMB levels. To synthesize the currently available evidence on these subjects, we performed a systematic review and meta-analysis.

2. Results {#sec2-cancers-11-01798}
==========

2.1. Identification of Studies and Study Characteristics {#sec2dot1-cancers-11-01798}
--------------------------------------------------------

Our initial search retrieved 1702 publications of which 122 articles were eligible for full-text screening ([Figure 1](#cancers-11-01798-f001){ref-type="fig"}). After full-text review of 122 publications and manual search of articles, 26 studies were finally eligible, with years of publication ranging from 2014 to 2019 ([Table 1](#cancers-11-01798-t001){ref-type="table"} and [Table 2](#cancers-11-01798-t002){ref-type="table"}) \[[@B5-cancers-11-01798],[@B20-cancers-11-01798],[@B21-cancers-11-01798],[@B22-cancers-11-01798],[@B23-cancers-11-01798],[@B25-cancers-11-01798],[@B26-cancers-11-01798],[@B27-cancers-11-01798],[@B28-cancers-11-01798],[@B29-cancers-11-01798],[@B30-cancers-11-01798],[@B31-cancers-11-01798],[@B32-cancers-11-01798],[@B33-cancers-11-01798],[@B34-cancers-11-01798],[@B35-cancers-11-01798],[@B36-cancers-11-01798],[@B37-cancers-11-01798],[@B38-cancers-11-01798],[@B39-cancers-11-01798],[@B40-cancers-11-01798],[@B41-cancers-11-01798],[@B42-cancers-11-01798],[@B43-cancers-11-01798],[@B44-cancers-11-01798],[@B45-cancers-11-01798]\]. The number of patients in each study ranged from 15 to 1662. Five articles were clinical trials with prospective assessment of TMB, four of which were RCTs. The other 21 studies were retrospective studies of cohorts or clinical trials, corresponding to 27 comparison pairs (high TMB arm versus low TMB arm). Ten comparisons studied patients with melanoma, and eight comparisons studied patients with non-small cell lung cancer (NSCLC). Gastric cancer, head and neck squamous cell cancer, small-cell lung cancer and urothelial carcinoma were addressed in one comparison each. All patients included in the enrolled studies were diagnosed as having advanced or metastatic diseases. For TMB detection, 12 studies used whole-exome sequencing (WES) while 14 used next-generation sequencing (NGS). The definition of high and low TMB was heterogeneous among the studies.

2.2. High TMB Group Versus Low TMB Group {#sec2dot2-cancers-11-01798}
----------------------------------------

Data on 3155 patients from 21 primary studies were included in the analysis ([Table 1](#cancers-11-01798-t001){ref-type="table"}), and all but one \[[@B5-cancers-11-01798]\] study were retrospective. Under a random-effects model, patients in the high TMB group receiving ICIs had significantly increased overall survival (OS) (hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.42 to 0.67) and progression-free survival (PFS) (HR 0.52, 95% CI 0.40 to 0.67) compared with patients in the low TMB group ([Figure 2](#cancers-11-01798-f002){ref-type="fig"} and [Figure 3](#cancers-11-01798-f003){ref-type="fig"}). Analysis under fixed effects showed a similar result ([Table S1](#app1-cancers-11-01798){ref-type="app"}), and heterogeneity was low in both meta-analyses (I^2^ = 0%). There was no evidence of publication bias, with no asymmetry in the funnel plots ([Figures S1 and S2](#app1-cancers-11-01798){ref-type="app"}).

Subgroup analyses ([Table 3](#cancers-11-01798-t003){ref-type="table"}) revealed that PD-L1 inhibitors (HR 0.35, 0.21 to 0.61) were associated with greater OS benefit in the high TMB population when compared with PD-1 inhibitors (HR 0.62, 95% CI 0.33 to 1.17) (I^2^ among subgroups = 44%). Detection of TMB by NGS (HR 0.44, 95% CI 0.33 to 0.59) was associated with a greater OS benefit in the high TMB population when compared with detection of TMB by WES (HR 0.73, 95% CI 0.50 to 1.06) (I^2^ among subgroups = 77%), while no such significant difference was found in the PFS outcome. Association of TMB level and OS or PFS was not heterogeneous among subgroups of cancer type (melanoma versus NSCLC), sample source (tumor tissue versus blood), detection method (WES vs NGS), study design (clinical trials vs cohorts) and the number of participants. There was a trend for better OS (HR 0.66, 95% CI 0.43 to 1.01) of patients with melanoma in the high TMB group compared to the low TMB group, and higher TMB was significantly associated with better PFS in patients with NSCLC (HR 0.53, 95% CI 0.30 to 0.93). The benefit of PFS or OS was not found in subgroups of TMB detection by blood sample, but this may be due to the small sample size and subsequent imprecision of the study estimates.

2.3. ICI Arm Versus Chemotherapy Arm, within High TMB Group or Low TMB Group {#sec2dot3-cancers-11-01798}
----------------------------------------------------------------------------

Data on 2557 patients were included in the analysis. The patient data were based on four RCTs ([Table 2](#cancers-11-01798-t002){ref-type="table"}), of which two RCTs prospectively analyzed TMB to test its role as a predictive biomarker. In patients with high TMB, the ICI arm showed prolonged OS (HR 0.69, 95% CI 0.50 to 0.95) and PFS (HR 0.66, 95% CI 0.47 to 0.92) compared to chemotherapy under a random-effects model ([Table S1, Figures S3 and S4](#app1-cancers-11-01798){ref-type="app"}). In patients with low TMB, there was a tendency for prolonged OS in the ICI arm (HR 0.78, 95% CI 0.60 to 1.00), but the association was not statistically significant (*p*-value = 0.051), and there was no PFS benefit (HR 1.14, 95% CI 0.83 to 1.57) under a random-effects model ([Table S1, Figures S5 and S6](#app1-cancers-11-01798){ref-type="app"}). Heterogeneity was low in all associations and a fixed effects model showed similar results to the random-effects model ([Table S1](#app1-cancers-11-01798){ref-type="app"}). There was no publication bias ([Figures S7--S10](#app1-cancers-11-01798){ref-type="app"}). A subgroup analysis was not available due to the small number of studies.

3. Discussion {#sec3-cancers-11-01798}
=============

This meta-analysis focuses on the association between TMB and long-term outcomes assessed by OS and PFS in cancer patients treated with ICIs. Integrating more than 5000 patient data with various advanced cancer types, our pooled analysis revealed a 47% risk reduction for death and a 48% risk reduction for disease progression in patients with high compared to low TMB undergoing ICI treatment. Such survival differences according to TMB level were not found in patients undergoing therapy other than ICIs \[[@B46-cancers-11-01798]\]. The ICIs compared to chemotherapies especially resulted in prolonged OS and PFS in patients with high TMB, whereas in patients with low TMB no PFS benefit was suggested. Therefore, our study suggests that TMB may be an effective predictive biomarker for ICI therapy. Even though our data are promising, more clinical investigations are needed to decide the optimal cut-off value that should be used for adding TMB to the routine clinical practice as a predictor of clinical efficacy.

TMB, which is defined as the total number of somatic mutations in the tumor exome \[[@B24-cancers-11-01798]\], was initially measured using WES \[[@B20-cancers-11-01798],[@B21-cancers-11-01798],[@B22-cancers-11-01798]\]. Thus, the utility of TMB was calculated primarily for the investigational study-based cohort. Subsequently, many of the studies included in this meta-analysis were small-sized, exploratory cohorts and contained patients with a variety of malignancies. Nevertheless, the favorable influence of high TMB on the long-term survival of patients under ICIs treatment did not significantly differ among studies with large versus small sample sizes (\>100 versus \<100). This tendency was also maintained when studies of patients with melanoma or NSCLC were analyzed separately.

Measuring TMB by WES has some limitations in daily clinical practice due to the tissue processing difficulty, time- and labor-intensiveness due to its large sequencing capacity and subsequent high costs. Due to these difficulties, a validated hybrid capture-based NGS platform was developed and is being used with several pragmatic advantages \[[@B47-cancers-11-01798],[@B48-cancers-11-01798]\]. However, the procedures differ in estimating the total number of somatic mutations. In WES, the germline variants are excluded after comparing data derived from normal tissue. The Foundation Medicine NGS approach, one of the most frequently used platforms, measures the number of base substitutions (synonymous and nonsynonymous mutations) in the coding region of targeted genes and defines TMB as the total number of mutations present in more than 5% allele frequency \[[@B49-cancers-11-01798],[@B50-cancers-11-01798]\]. Previous reports demonstrated significant correlations in measuring TMB between using WES and these panel-based analyses \[[@B23-cancers-11-01798],[@B26-cancers-11-01798],[@B29-cancers-11-01798],[@B51-cancers-11-01798],[@B52-cancers-11-01798]\], although some studies suggested a certain panel size as the minimum requirement for a correct estimation \[[@B51-cancers-11-01798],[@B53-cancers-11-01798]\]. In our study, the impact of TMB on OS was statistically significant in studies that used NGS but not in studies that used WES.

In our study, subgroup analyses demonstrated that TMB measurement using panel-based sequencing was associated with a higher OS benefit compared to detection of TMB by WES with moderate heterogeneity. In clinical settings, cost is an important issue for the wide-spread use of diagnostic tools. Consequently, the number of patients using the panel-based sequencing was higher than that of WES-based analysis, and one study, which included an exceptionally large number of patients, used panel-based sequencing, and this might have influenced the results of our meta-analysis \[[@B32-cancers-11-01798]\]. In addition, studies with panel-based NGS sequencing may select the cut off using the optimal value that could maximize the survival difference between patients with high and low TMB. These characteristics of the included studies in our meta-analysis might have caused bias to favor outcomes from panel-based sequencing tests over WES-driven data, rather than one method being superior than the other. Previous studies have reported high correlation of TMB measured by NGS and WES \[[@B39-cancers-11-01798],[@B54-cancers-11-01798]\].

Our data also showed that the effect of ICIs on OS was higher in TMB-high patients treated with PD-L1 inhibitors compared to PD-1 inhibitors or cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) inhibitors. This may be related to differences in the mechanism of action of the different ICIs. For example, PD-1 blocking antibodies inhibit the interaction between PD-L1 and PD-1, but they do not inhibit PD-L1 from interacting with CD80 \[[@B55-cancers-11-01798]\]. In contrast, both these interactions with PD-L1 will be blocked by PD-L1-blocking antibodies, but this does not prevent PD-1 from interacting with PD-L2 \[[@B55-cancers-11-01798]\]. In addition, binding of PD-L1 antibodies to tumor-associated macrophages (TAMs) may trigger macrophage proliferation, survival and activation, triggering macrophage-mediated antitumor activity \[[@B56-cancers-11-01798]\]. The CTLA-4 antibodies have a distinct mechanism of action targeting different receptor interactions from PD-L1/PD-1 inhibitors that may also impact a different phase of the anti-tumor immune response. These mechanistic basics might lead to the differences in the predictive impact of TMB for various ICIs. Further studies are needed to clarify these observed differences in more detail.

Conforti and colleagues \[[@B57-cancers-11-01798]\] reported a difference in immunotherapy efficacy according to patient sex. The HRs for OS in patients treated with immunotherapy compared with controls was 0.72 (95% CI 0.65 to 0.79) in men and 0.86 (95% CI 0.79 to 0.93) in women (*p* = 0.0019) \[[@B57-cancers-11-01798]\]. The reason for the observed sex difference was not clear, but differences in behavioral and lifestyle differences were discussed as causative factors \[[@B58-cancers-11-01798]\]. In contrast, Wallis et al. \[[@B59-cancers-11-01798]\] recently updated an earlier meta-analysis and demonstrated no difference in the efficacy of ICIs according to sex.

Melanoma and NSCLC have high mutational burdens compared with other tumors \[[@B51-cancers-11-01798],[@B60-cancers-11-01798]\], and this was regarded to be the reason that the efficacy of ICIs is most prominent in these cancers. Interestingly, among 19 different cancer types from The Cancer Genome Atlas (TCGA) dataset, mean TMB was only higher in men than in women for cutaneous melanoma \[[@B61-cancers-11-01798]\]. Considering the favorable prognostic impact of high TMB in our meta-analysis, the reduced efficacy of ICIs in female melanoma patients may originate from the relatively lower TMB levels rather than a true sex difference. It should be noted that even though the overall effect size was not significantly different between men and women in the Wallis and colleagues study \[[@B59-cancers-11-01798]\] (HR 0.75, 95% CI (0.69 to 0.81) in men versus HR 0.77, 95% CI (0.67 to 0.88) in women), a reduced efficacy of immunotherapy in women was still noted in the subgroup analysis of melanoma patients (HR 0.68, 95% CI (0.48 to 0.97) in men versus HR 0.83, 95% CI (0.68 to 1.00) in women). Further large-scale clinical investigations should be conducted to validate the real effect of sex or lifestyle factors on immunotherapy efficacy in relation to gender-specific differences in TMB.

Clarifying the association of TMB with other known predictors of ICI therapy may be useful. Association of microsatellite instability and TMB is reported to be complex and differs across different cancer types \[[@B62-cancers-11-01798]\], while PD-L1 expression is known to predict outcome independently from TMB \[[@B63-cancers-11-01798],[@B64-cancers-11-01798]\]. The association of TMB with other clinicopathologic variables known to effect response to ICI therapy such as age, body mass index \[[@B65-cancers-11-01798]\], concomitant medications, gut microbiota \[[@B66-cancers-11-01798]\], mismatch repair status, tumor-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio \[[@B1-cancers-11-01798]\] remains to be elucidated. Recent studies have also demonstrated that genetic driver events, intratumoral heterogeneity, mutational signature and T-cell inflamed gene expression profile may be used to identify patients showing responses to ICIs \[[@B30-cancers-11-01798],[@B67-cancers-11-01798],[@B68-cancers-11-01798]\]. Though several of these factors may be interrelated, these findings suggest that TMB status alone may be insufficient in determining which patients should be offered ICIs. Besides adequate and clinically adapted cut-off values based on the patients' stage or clinical situation, we suggest a combined approach of these various biomarkers to be evaluated together, as the clinical challenge remains to define non-responders rather than responders. This goal to discriminate non-responders rather than responders should be taken into consideration when defining cut-off values in the cohort of recurrent or advanced disease, as demonstrated by our eligible studies. This might differ for early-stage patients, where a cut-off should identify high-risk patients with the highest probability to benefit from ICI treatment compared to other treatment strategies. Therefore, we suggest a combined approach utilizing a few predictive markers in the future dividing the patient population by subgroups and assessing survival outcomes separately. This may particularly be relevant when the biomarkers are independently predictive, such as PD-L1 and TMB \[[@B63-cancers-11-01798],[@B64-cancers-11-01798]\]. To take account of the combination of many biomarkers to predict response to therapy, one may develop multivariable prediction models (such as logistic regression models) \[[@B69-cancers-11-01798],[@B70-cancers-11-01798]\] or scoring systems \[[@B71-cancers-11-01798]\] which should be followed by its prospective validation in other independent cohorts. Finally, proposed methods should be validated in large-sized RCTs to be utilized in real-world clinics.

There are some remaining issues and limitations in the use of TMB in routine clinical practice. First, even though our study demonstrated that a high TMB level could be interpreted as a positive predictive factor in patients treated with ICIs, deciding the exact cut-off value defining a high TMB level remains a considerable task that should be completed prior to its use in clinical practice. In our eligible studies, cut-off values varied significantly, even across studies of patient groups with the same malignancies. The tendency for HR to become lower as the threshold defining the high TMB increased was observed in several studies \[[@B26-cancers-11-01798],[@B27-cancers-11-01798],[@B32-cancers-11-01798]\]. It may be advantageous to raise the TMB standard to identify patients who will benefit most from ICI treatment, though this may also result in potential responding patients being excluded from ICI therapy. In future studies, an optimal TMB threshold may initially be identified by setting a cut-off of optimal sensitivity and specificity of survival and by utilizing molecular indicators of response to ICI therapy in a discovery cohort, following its prospective validation in another independent cohort \[[@B22-cancers-11-01798],[@B72-cancers-11-01798]\]. The proposed threshold should then be validated in large-sized RCTs to be routinely used in clinical practice.

Another issue regarding TMB as a predictive biomarker is its potential variation over time. For example, TMB may differ with age: Children's mutational burden of glioblastoma was lower than that of adults \[[@B51-cancers-11-01798]\] and was also changed within the same patient. Nathanson and colleagues \[[@B73-cancers-11-01798]\] reported that TMB was significantly higher in melanoma patients with clinical benefit than in non-responders. However, this positive correlation was only observed when TMB evaluation was performed on patient samples collected prior to treatment and was not maintained when using patient samples collected after the initiation of ICI therapy \[[@B73-cancers-11-01798]\]. Thus, it was suggested that it would be ideal to have TMB assessment on tissue obtained immediately prior to therapy \[[@B27-cancers-11-01798]\]. In our meta-analysis, it was not possible to compare the efficacy of TMB according to the time point at which it was assessed, because many included studies did not report the exact time point at which TMB was assessed.

This study has several limitations. The included studies are apt to have non-generalizable results and may be more representative of an insured, high-income population due to selection and referral bias. Many eligible studies (especially basic research papers) had small sample sizes and often did not present data necessary for analysis, possibly leading to selection bias and exclusion of other meaningful findings. Most eligible studies of high TMB versus low TMB analyses studied NSCLC, melanoma or non-specific tumor type and, therefore, the results may be hard to generalize to other cancer types. Modality of TMB detection (NGS versus WES) and tissue (blood versus tumor) also differed significantly. Definition of high and low TMB varied across the studies, further contributing to the potential heterogeneity. However, the observed heterogeneity (I^2^) within the main analyses or within most subgroups were low with consistent results found across the studies, supporting the robust association of higher benefit of ICIs in the high TMB group compared to the low TMB group despite these differences. Therefore, TMB may be an effective biomarker to predict survival in patients undergoing ICI treatment.

4. Materials and Methods {#sec4-cancers-11-01798}
========================

This systematic review and meta-analysis were performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B74-cancers-11-01798]\] ([Table A1](#cancers-11-01798-t0A1){ref-type="table"}).

4.1. Literature Search Strategy and Eligibility Criteria {#sec4dot1-cancers-11-01798}
--------------------------------------------------------

Three investigators (JYK, JK and JIS) searched PubMed, Embase, CENTRAL and clinicaltrials.gov from inception to 6 August 2019 to identify retrospective studies or clinical trials of ICIs that reported HRs for OS and/or PFS according to TMB. The search was performed with key words such as tumor mutational burden, mutational load and immune checkpoint inhibitors (full search strategy available in [Appendix B](#app3-cancers-11-01798){ref-type="app"}). There was no language restriction. Reference lists of relevant studies were also manually searched.

We searched for observational studies or RCTs studying the role of TMB as the predictive biomarker of ICI therapy for cancer patients. The eligibility criteria were as follows. First, the study had to report patient group(s) with any type of cancer treated with inhibitors of PD-1 (nivolumab, pembrolizumab, or toripalimab), PD-L1 (atezolizumab or avelumab), or CTLA-4 (ipilimumab or tremelimumab), alone or in combination with other ICIs. Second, the TMB of the included patients had to be assessed and reported. TMB was assessed by WES or a hybrid capture-based targeted NGS panel, both of which are available in clinical practice. Third, studies were required to either report OS and/or PFS comparing patient groups with high and low TMB or report OS and/or PFS comparing patient groups with ICI treatment and chemotherapy (any kind of chemotherapy) within patient groups with either high or low TMB. The definition of high or low TMB followed that of the individual studies. Fourth, the survival data had to be reported as a calculable metric such as HR. Studies that did not report survival as a calculable metric, in vitro studies, animal studies, conference abstracts and reviews were excluded. When there was a duplicate population among two or more studies, we included the more recent and complete study.

4.2. Data Extraction {#sec4dot2-cancers-11-01798}
--------------------

Three investigators (JYK, JK and JIS) extracted the data, and discrepancies were resolved by discussion and consensus. From eligible articles, we extracted the following: Name of the first author, published year, study design, type of cancer, treatment regimen, source of the sample for assessing TMB, TMB detection method, median TMB and its range, TMB threshold, the numbers of patients in high/low TMB groups and survival outcomes represented as HRs and corresponding 95% CIs.

4.3. Statistical Analysis {#sec4dot3-cancers-11-01798}
-------------------------

We performed the following meta-analyses: (1) OS or PFS in the high TMB group versus low TMB group and (2) OS or PFS in ICI arm versus chemotherapy arm within the high TMB group or low TMB group. All analyses were conducted using R version 3.5.1 (R-project, Institute for Statistics and Mathematics) and "metafor" package \[[@B75-cancers-11-01798]\]. We calculated the summary effect size, 95% CI and *p*-values under random- and fixed-effects models. We presented results under random effects because the clinical settings were expected to be heterogeneous across the studies. The heterogeneity among the included studies was evaluated using the I^2^ statistic and its *p*-value of χ2-based Cochran's Q test. I^2^ \> 50% and \>75% are considered to indicate large and very large heterogeneity, respectively \[[@B76-cancers-11-01798]\]. To investigate the potential source of variation of the predictive value of TMB, we performed subgroup analyses of treatment regimen, cancer type, TMB sample source (tumor tissue versus blood), TMB detection method (WES versus NGS), study design and the number of participants (\<100 versus \>100). We assessed publication bias by visual inspection of funnel plots and Egger's test of asymmetry \[[@B77-cancers-11-01798]\]. In Egger's test, publication bias was claimed at *p* \< 0.10. All statistical tests were two-tailed, and *p* \< 0.05 was considered statistically significant.

5. Conclusions {#sec5-cancers-11-01798}
==============

Our systematic review demonstrated that the TMB may predict long-term outcomes in patients who received ICIs and encourages its evaluation as a predictive marker of ICI therapy. Future large RCTs of ICIs for patients with various cancer types should evaluate the role of TMB in identifying patient groups that may benefit from ICIs.

The following are available online at <https://www.mdpi.com/2072-6694/11/11/1798/s1>, Table S1: Results of random-effects, fixed-effects, heterogeneity and Egger *p*-value of all meta-analyses, Figure S1: Overall survival, high TMB versus low TMB, funnel plot, Figure S2: Progression-free survival, high TMB versus low TMB, funnel plot, Figure S3: Overall survival, high TMB, immunotherapy versus chemotherapy, random-effects model, Figure S4: Progression-free survival, high TMB, immunotherapy versus chemotherapy, random-effects model, Figure S5: Overall survival, low TMB, immunotherapy versus chemotherapy, random-effects model, Figure S6: Progression-free survival, low TMB, immunotherapy versus chemotherapy, random-effects model, Figure S7: Overall survival, high TMB, immunotherapy versus chemotherapy, funnel plot, Figure S8: Progression-free survival, high TMB, immunotherapy versus chemotherapy, funnel plot, Figure S9: Overall survival, low TMB, immunotherapy versus chemotherapy, funnel plot, Figure S10: Progression-free survival, low TMB, immunotherapy versus chemotherapy, funnel plot.
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  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title                                1    Identify the Report as a Systematic Review, Meta-Analysis, or Both                                                                                                                                                                                                                                            0
  ABSTRACT                                                                                                                                                                                                                                                                                                                                                
  Structured summary                   2    Provide a structured summary including, as applicable: Background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.   0
  INTRODUCTION                                                                                                                                                                                                                                                                                                                                            
  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                1
  Objectives                           4    Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).                                                                                                                                                    1
  METHODS                                                                                                                                                                                                                                                                                                                                                 
  Protocol and registration            5    Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.                                                                                                                                 N/A
  Eligibility criteria                 6    Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.                                                                                                        11--12
  Information sources                  7    Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.                                                                                                                                    11
  Search                               8    Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.                                                                                                                                                                                 [Appendix B](#app3-cancers-11-01798){ref-type="app"}
  Study selection                      9    State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).                                                                                                                                                     11--12
  Data collection process              10   Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.                                                                                                                                    12
  Data items                           11   List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                         12
  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        N/A
  Summary measures                     13   State the principal summary measures (e.g., risk ratio, difference in means).                                                                                                                                                                                                                                 12
  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysis.                                                                                                                                                       12
  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).                                                                                                                                                                  12
  Additional analyses                  16   Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                              12
  RESULTS                                                                                                                                                                                                                                                                                                                                                 
  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               2, [Figure 1](#cancers-11-01798-f001){ref-type="fig"}
  Study characteristics                18   For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.                                                                                                                                                                  2, [Table 1](#cancers-11-01798-t001){ref-type="table"} and [Table 2](#cancers-11-01798-t002){ref-type="table"}
  Risk of bias within studies          19   Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).                                                                                                                                                                                                     N/A
  Results of individual studies        20   For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.                                                                                                      [Figure 2](#cancers-11-01798-f002){ref-type="fig"} and [Figure 3](#cancers-11-01798-f003){ref-type="fig"}, [Figures S3--S6](#app1-cancers-11-01798){ref-type="app"}
  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       2, [Table 1](#cancers-11-01798-t001){ref-type="table"} and [Table 2](#cancers-11-01798-t002){ref-type="table"}, [Table S1](#app1-cancers-11-01798){ref-type="app"}
  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               2, [Table S1, Figures S1, S2, S7--S10](#app1-cancers-11-01798){ref-type="app"}
  Additional analysis                  23   Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                       [Table 3](#cancers-11-01798-t003){ref-type="table"}
  DISCUSSION                                                                                                                                                                                                                                                                                                                                              
  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).                                                                                                                          9--11
  Limitations                          25   Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).                                                                                                                                                 11
  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       12
  FUNDING                                                                                                                                                                                                                                                                                                                                                 
  Funding                              27   Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.                                                                                                                                                                    13(none)
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
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The last search performed on 6 August 2019 yielded 776 results:

Search term: (mutational burden\* OR mutation burden\* OR mutational load\* OR mutation load\*) AND (nivolumab OR pembrolizumab OR atezolizumab OR avelumab OR durvalumab OR ipilimumab OR immunotherap\* OR PD-1 OR PD-L1 OR CTLA-4 OR PD1 OR PDL1 OR CTLA4 OR PDCD1 OR CD274 OR BMS-936558 OR BMS-936559 OR MK-3475 OR MPDL3280A OR MEDI4736 OR MSB0010718C OR BMS-734016 OR MDX-010 OR MDX-101 OR immune checkpoint\* OR checkpoint blockade\*)
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cancers-11-01798-t001_Table 1

###### 

Characteristics of studies included in the meta-analysis of the high tumor mutational burden (TMB) group versus low TMB group.

  Study                                                Type of Study                              Malignancy               Type of Immunotherapy          Sample Source   Detection Method   TMB Cutoff                          Median TMB (range)   Number of Patients (High/Low TMB)   Outcome
  ---------------------------------------------------- ------------------------------------------ ------------------------ ------------------------------ --------------- ------------------ ----------------------------------- -------------------- ----------------------------------- ---------
  Balar et al. 2017 \[[@B44-cancers-11-01798]\]        Retrospective analysis of clinical trial   Urothelial carcinoma     Atezolizumab                   Tumor           FoundationOne      ≥16/MB                              8.1 (0.9--62.2)      97 (NR)                             OS
  Chae et al. 2018 \[[@B28-cancers-11-01798]\]         Retrospective cohort                       NSCLC                    PD-1/PD-L1 inhibitor           Tumor           FoundationOne      ≥15/MB                              8 (1--55)            34 (NR)                             OS, PFS
  Chae et al. 2019a \[[@B41-cancers-11-01798]\]        Retrospective cohort                       NSCLC                    Immune checkpoint inhibitors   Blood           Guardant360        NR (median)                         NR                   20 (10/10)                          OS, PFS
  Chae et al. 2019b \[[@B41-cancers-11-01798]\]        Retrospective cohort                       NSCLC                    Immune checkpoint inhibitors   Blood           Guardant360        NR (median)                         NR                   12 (6/6)                            OS, PFS
  Cristescu et al. 2018a \[[@B30-cancers-11-01798]\]   Retrospective analysis of clinical trial   Pan-tumor                Pembrolizumab                  Tumor           WES                \>102.5                             NR                   119 (37/82)                         PFS
  Cristescu et al. 2018b \[[@B30-cancers-11-01798]\]   Retrospective analysis of clinical trial   Melanoma                 Pembrolizumab                  Tumor           WES                \>191.5                             NR                   89 (59/30)                          PFS
  Cristescu et al. 2018c \[[@B30-cancers-11-01798]\]   Retrospective analysis of clinical trial   HNSCC                    Pembrolizumab                  Tumor           WES                \>86                                NR                   107 (54/53)                         PFS
  Fang et al. 2019 \[[@B39-cancers-11-01798]\]         Retrospective analysis of clinical trial   NSCLC                    PD-1/PD-L1 inhibitor           Tumor           WES                ≥157 (top tertile)                  87 (4--1528)         73 (25/48)                          PFS
  Goodman et al. 2017 \[[@B27-cancers-11-01798]\]      Retrospective cohort                       Various                  Various                        Tumor           FoundationOne      ≥20/MB                              6 (1--347)           151 (38/113)                        OS, PFS
  Hamid et al. 2019 \[[@B37-cancers-11-01798]\]        Retrospective analysis of clinical trial   Melanoma                 Atezolizumab                   Tumor           FoundationOne      ≥16/MB                              NR                   23 (12/11)                          OS, PFS
  Hellmann et al. 2018 \[[@B23-cancers-11-01798]\]     Retrospective analysis of clinical trial   NSCLC                    Nivolumab plus ipilimumab      Tumor           WES                \>158 (median)                      158                  75 (37/38)                          PFS
  Hugo et al. 2016 \[[@B31-cancers-11-01798]\]         Retrospective cohort                       Melanoma                 Pembrolizumab or nivolumab     Tumor           WES                ≥577 (bottom tertile)               489 (73--3985)       37 (13/24)                          OS
  Johnson et al. 2016 \[[@B29-cancers-11-01798]\]      Retrospective cohort                       Melanoma                 PD-1/PD-L1 inhibitor           Tumor           FoundationOne      \>23.1/MB                           NR                   65 (27/38)                          OS, PFS
  Khagi et al. 2017 \[[@B43-cancers-11-01798]\]        Retrospective cohort                       Various                  Various                        Blood           Guardant360        \>3 total ctDNR alterations         2 (0--20)            69 (20/49)                          OS, PFS
  Le et al. 2015 \[[@B5-cancers-11-01798]\]            Clinical trial                             Various                  Pembrolizumab                  Tumor           WES                NR                                  NR                   15 (NR)                             OS, PFS
  Ricciuti et al. 2019 \[[@B40-cancers-11-01798]\]     Retrospective cohort                       Small-cell lung cancer   Immune checkpoint inhibitors   Tumor           NGS (OncoPanel)    \>9.7/MB (median)                   9.8 (1.2--31.2)      52 (26/26)                          OS, PFS
  Rizvi et al. 2015a \[[@B22-cancers-11-01798]\]       Retrospective cohort                       NSCLC                    Pembrolizumab                  Tumor           WES                \>209 (median)                      NR                   18 (9/9)                            PFS
  Rizvi et al. 2015b \[[@B22-cancers-11-01798]\]       Retrospective cohort                       NSCLC                    Pembrolizumab                  Tumor           WES                \>200 (median)                      NR                   16 (8/8)                            PFS
  Rizvi et al. 2018 \[[@B26-cancers-11-01798]\]        Retrospective cohort                       NSCLC                    Immune checkpoint inhibitors   Tumor           WES                \>324                               171 (1--1147)        49 (12/37)                          PFS
  Roszik et al. 2016 \[[@B34-cancers-11-01798]\]       Retrospective cohort                       Melanoma                 Ipilimumab                     Tumor           NGS                \>100                               NR                   76 (57/19)                          OS
  Samstein et al. 2019 \[[@B32-cancers-11-01798]\]     Retrospective cohort                       Various                  Immune checkpoint inhibitors   Tumor           NGS (MSK-IMPACT)   90th percentile of each histology   NR                   1662 (NR)                           OS
  Snyder, et al. 2014a \[[@B20-cancers-11-01798]\]     Retrospective cohort                       Melanoma                 Ipilimumab or tremelimumab     Tumor           WES                \>100                               NR                   25 (10/15)                          OS
  Snyder et al. 2014b \[[@B20-cancers-11-01798]\]      Retrospective cohort                       Melanoma                 Ipilimumab or tremelimumab     Tumor           WES                \>100                               NR                   39 (17/22)                          OS
  Van Allen et al. 2015 \[[@B21-cancers-11-01798]\]    Retrospective cohort                       Melanoma                 Ipilimumab                     Tumor           WES                ≥202 (median)                       197 (7--5854)        110 (55/55)                         OS, PFS
  Wang et al. 2019 \[[@B38-cancers-11-01798]\]         Retrospective analysis of clinical trial   Gastric cancer           Toripalimab                    Tumor           WES                ≥12/MB                              NR                   54 (12/42)                          OS, PFS
  Yusko et al. 2019a \[[@B35-cancers-11-01798]\]       Retrospective analysis of clinical trial   Melanoma                 Nivolumab or ipilimumab        Tumor           WES                NR                                  171                  30 (NR)                             OS
  Yusko et al. 2019b \[[@B35-cancers-11-01798]\]       Retrospective analysis of clinical trial   Melanoma                 Nivolumab or ipilimumab        Tumor           WES                NR                                  159                  38 (NR)                             OS

Abbreviations: TMB, tumor mutational burden; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; WES, whole-exome sequencing; NGS, next-generation sequencing; NR, not reported; OS, overall survival; PFS, progression-free survival.

cancers-11-01798-t002_Table 2

###### 

Characteristics of studies included in the meta-analysis of the immunotherapy group versus chemotherapy group.

  Study                                                  Type of Study                   Malignancy             Immunotherapy versus Chemotherapy Comparison                     Sample Source   Detection Method   TMB Cutoff           Number of Patients with High/Low TMB   Outcome
  ------------------------------------------------------ ------------------------------- ---------------------- ---------------------------------------------------------------- --------------- ------------------ -------------------- -------------------------------------- ---------
  Carbone et al. 2017 \[[@B33-cancers-11-01798]\]        Retrospective analysis of RCT   NSCLC                  Nivolumab versus platinum-based chemotherapy                     Tumor           WES                ≥243 (top tertile)   107/205                                OS, PFS
  Gandara et al. 2018a \[[@B42-cancers-11-01798]\]       Retrospective analysis of RCT   NSCLC                  Atezolizumab versus docetaxel                                    Blood           FoundationOne      ≥16/MB               63/148                                 OS, PFS
  Gandara et al. 2018b \[[@B42-cancers-11-01798]\]       Retrospective analysis of RCT   NSCLC                  Atezolizumab versus docetaxel                                    Blood           FoundationOne      ≥16/MB               158/425                                OS, PFS
  Hellmann et al. 2019 \* \[[@B45-cancers-11-01798]\]    RCT                             NSCLC                  Nivolumab plus ipilimumab versus platinum doublet chemotherapy   Tumor           FoundationOne      ≥10/MB               299/380                                OS
  Hellmann et al. 2018a \* \[[@B25-cancers-11-01798]\]   RCT                             NSCLC                  Nivolumab plus ipilimumab versus platinum doublet chemotherapy   Tumor           FoundationOne      ≥10/MB               299/380                                PFS
  Hellmann et al. 2018b \[[@B25-cancers-11-01798]\]      RCT                             NSCLC                  Nivolumab versus platinum doublet chemotherapy                   Tumor           FoundationOne      ≥13/MB               150/78                                 PFS
  Powles et al. 2018 \[[@B36-cancers-11-01798]\]         RCT                             Urothelial carcinoma   Atezolizumab versus platinum-based chemotherapy                  Blood           FoundationOne      ≥9.65/MB (median)    274/270                                OS

Abbreviations: NR, not reported; NSCLC, non-small cell lung cancer; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; TMB, tumor mutational burden; WES, whole-exome sequencing. \* Data from identical population.

cancers-11-01798-t003_Table 3

###### 

Results of the subgroup analysis of the high TMB group versus low TMB group.

  Subgroup                                  Overall Survival   Progression-Free Survival                                                               
  ----------------------------------------- ------------------ --------------------------- --------- ---- -- ---- --------------------- --------- ---- --
  All studies                               19                 0.53 (0.42 to 0.67)         \<0.001   0       19   0.52 (0.40 to 0.67)   \<0.001   0    
  Subgroup analysis                                                                                                                                    
  Treatment                                 0                                                                \-                                        
  PD-1/PD-L1 inhibitors                     7                  0.43 (0.29 to 0.64)         \<0.001   0       11   0.51 (0.35 to 0.73)   \<0.001   0    
  CTLA-4 inhibitors                         4                  0.57 (0.30 to 1.09)         0.087     0                                                 
  PD-1 inhibitors versus PD-L1 inhibitors   44                                             \-                                                          
  PD-1 inhibitors                           3                  0.62 (0.33 to 1.17)         0.14      0       7    0.54 (0.36 to 0.81)   0.003     0    
  PD-L1 inhibitors                          2                  0.35 (0.21 to 0.61)         \<0.001   0                                                 
  Cancer type                               0                                              0                                                           
  Melanoma                                  9                  0.66 (0.43 to 1.01)         0.056     0       4    0.47 (0.21 to 1.05)   0.066     32   
  NSCLC                                     3                  1.80 (0.21 to 15.60)        0.59      19      8    0.53 (0.30 to 0.93)   0.028     0    
  Sample source                             0                                              0                                                           
  Tumor tissue                              16                 0.52 (0.41 to 0.66)         \<0.001   0       16   0.50 (0.38 to 0.66)   \<0.001   0    
  Blood                                     3                  1.22 (0.21 to 7.21)         0.83      39      3    0.84 (0.26 to 2.70)   0.77      18   
  Detection method                          77                                             0                                                           
  WES                                       8                  0.73 (0.50 to 1.06)         0.094     0       11   0.56 (0.41 to 0.77)   \<0.001   0    
  NGS                                       11                 0.44 (0.33 to 0.59)         \<0.001   0       8    0.44 (0.26 to 0.73)   0.001     6    
  Data source                               0                                              0                                                           
  Clinical trials                           6                  0.57 (0.35 to 0.92)         0.020     32      8    0.52 (0.36 to 0.75)   \<0.001   0    
  Cohorts                                   13                 0.50 (0.37 to 0.68)         \<0.001   0       11   0.51 (0.35 to 0.76)   \<0.001   1    
  Number of participants                    0                                              0                                                           
  ≥100 participants                         3                  0.53 (0.37 to 0.75)         \<0.001   0       4    0.56 (0.37 to 0.85)   0.007     7    
  \<100 participants                        16                 0.53 (0.39 to 0.72)         \<0.001   0       15   0.49 (0.34 to 0.69)   \<0.001   0    

Abbreviations: CI, confidence interval; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; HR, hazard ratio; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; WES, whole-exome sequencing. \* Significant associations are shown in bold.
